- Company
- Samsung Bioepis’ Stelara biosimilar is approved in Europe
- by Chon, Seung-Hyun Apr 24, 2024 05:44am
- Samsung Bioepis announced on the 23rd that the European Commission (EC) granted marketing authorization for its Stelara biosimilar Pyzchiva. The final marketing authorization comes 2 months after Pyzchiva received a positive opinion for marketing authorization from the European Medicines Agency (EMA)’s Committee for Medicinal Products
- Company
- Prostate cancer drug Pluvicto’s approval imminent in Korea
- by Eo, Yun-Ho Apr 24, 2024 05:44am
- The new metastatic castration-resistant prostate cancer drug ‘Pluvicto’ is set to soon be commercialized in Korea. According to industry sources, the Ministry of Food and Drug Safety is in the final stages of reviewing Novartis Korea's targeted radioligand therapy ‘Pluvicto (lutetium (177Lu) vipivotide tetraxetan)’ for its marketing a
- Policy
- Prolia and Ryaltris adjust drug pricing
- by Lee, Tak-Sun Apr 23, 2024 05:40am
- Amgen Korea and Chong Kun Dang Pharmaceutical will voluntarily reduce the price of 'Prolia,' which they are jointly selling. As the government expanded the administration guidance of osteoporosis medicines, Prolia, which is expected to see an increase in sales following the reimbursement expansion, voluntarily adjusted the ceiling price
- Company
- Pharmbio wins over Novartis’ Revolade in patent dispute
- by Kim, Jin-Gu Apr 23, 2024 05:37am
- Pharmbio Korea has won the first trial in a patent dispute against 'Revolade (eltrombopag olamine),' a treatment for primary immune thrombocytopenia (ITP), following SK Plasma. Pharmbio Korea received a generic biological license application (BLA) prior to winning the first trial, but the company may face a high risk in launching the prod
- Policy
- HK inno.N starts developing a Lixiana generic
- by Lee, Hye-Kyung Apr 23, 2024 05:36am
- HK inno.N is joining the race to develop a generic version of the NOAC (novel oral anticoagulant) drug Lixiana (edoxaban). The Ministry of Food and Drug Safety recently approved clinical trials to evaluate the bioequivalence of the Lixiana generic ‘IN-G00002’ and IN-R00002 (Lixiana). The IN-G00002 bioequivalence trial will evaluate t
- Company
- Skyrizi approved for palmoplantar pustulosis
- by Son, Hyung-Min Apr 23, 2024 05:36am
- Whether Skyrizi will be able to address the patients’ unmet needs for patients with palmoplantar pustulosis with its ease in administration is receiving attention. As a maintenance therapy, Skyrizi can be administered every 12 weeks, making it easier to dose than other treatments. Doctors have analyzed that the use of such new biological
- Company
- Novartis fosters innovative talent through focus on purpose
- by Eo, Yun-Ho Apr 23, 2024 05:36am
- Novartis Korea has gone through a period of transformation over the past few years. As part of the global headquarters' large-scale reorganization, the company's long-established oncology and pharmaceutical businesses were merged. Although the businesses were operating under one name, Novartis, the two departments were operated independen
- Policy
- Atopic dermatitis drug Adtralza will be reimb in May
- by Lee, Jeong-Hwan Apr 22, 2024 05:45am
- Leo Pharma Korea’s atopic dermatitis treatment, Adtralza (tralokinumab), will be reimbursed from May 1 in Korea. The reimbursement standards for osteoporosis drugs will also be improved, and patients who show some improvement in bone mineral density will be able to continue receiving reimbursement. As such, JW Pharmaceuticals' iron injec
- Policy
- KMPG ‘We ask for the prompt reimbursement of Xpovio’
- by Kim, Jung-Ju Apr 22, 2024 05:45am
- Patients’ demand for the reimbursement listing of ‘Xpovio 20mg (selinexor),’ a new drug for multiple myeloma that was developed by the Chinese pharmaceutical company Antengene, is growing. The patients are claiming that they are becoming ‘medical poor’ due to the delay in the reimbursement of the only option available in the area. Xp
- Company
- AstraZeneca focuses on improving competitiveness of NMOSD
- by Eo, Yun-Ho Apr 22, 2024 05:45am
- AstraZeneca focuses on improving the competitiveness of neuromyelitis optica spectrum disorder (NMOSD) treatments. The company aims to target the market as its new blockbuster drugs, 'Soliris (eculizumab),' which is used to treat paroxysmal nocturnal hemoglobinuria (PNH), and 'Ultomiris (ravulizumab),' which is a treatment for neuromyelit
